glp-1 receptor agonists in pediatric and adolescent obesity JAMA Oral GLP-1-Based Therapeutics in the
Description
GLP-1/glucagon receptor co-agonism for treatment of obesity

[Crossref] [PubMed] Gelaye B, Sacco S, Brown WJ, et al
Eye 38:13741379

Why It Matters for Patients Targeting stubborn fat: Belly fat and liver fat are among the most harmful types of fat for long-term health
Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects

[34] Bossart, Martin, et al
